Skip to content

Catalyst Biosciences

Primary Menu

About
Partnering
Science
- Overview
- Publications
Investors
Contact

Investors

Press Releases

Keyword Search

Year

August 10, 2022

Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board

August 3, 2022

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card

August 1, 2022

Catalyst Biosciences Publishes New Investor Presentation

August 1, 2022

Catalyst Biosciences Announces Support from Largest Single Stockholder

July 19, 2022

Catalyst Biosciences Sends Letter to Stockholders

July 6, 2022

Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling

June 29, 2022

Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

May 23, 2022

Catalyst Biosciences Sells Complement Portfolio for $60 Million

May 9, 2022

Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

March 31, 2022

Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

March 15, 2022

Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology

February 17, 2022

Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives

January 25, 2022

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Overview
Press Releases
Events and Presentations
Financials & Filings
Stock Information
- Stock Quote
- Stock Chart
Corporate Governance
Investor FAQ

Shareholder Tools

Print Page
RSS Feeds
Email Alerts

About
Partnering
Science
- Overview
- Publications
Investors
Contact

Catalyst Biosciences

Catalyst Biosciences
| 611 Gateway Blvd., Suite 710,
South San Francisco, CA 94080

© Catalyst Biosciences. All rights reserved.
Terms of Use Privacy Policy Cookie Notice

Twitter
LinkedIn
Facebook